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While small bone defects heal spontaneously, large bone defects need surgical intervention for bone transplantation. Autologous
bone grafts are the best and safest strategy for bone repair. An alternative method is to use allogenic bone graft. Both methods
have limitations, particularly when bone defects are of a critical size. In these cases, bone constructs created by tissue engineering
technologies are of utmost importance. Cells are one main component in the manufacture of bone construct. A few cell types,
including embryonic stem cells (ESCs), adult osteoblast, and adult stem cells, can be used for this purpose. Mesenchymal stem
cells (MSCs), as adult stem cells, possess characteristics that make them good candidate for bone repair. This paper discusses
diﬀerent aspects of MSCs that render them an appropriate cell type for clinical use to promote bone regeneration.
1.Introduction
Boneisahighlyspeciﬁc,dynamictissuecapableofmaintain-
ingviabilityundermechanicalstressandexternalcontinuous
compression. This capability of bone tissue diminishes with
increasing age [1]. Furthermore, small bone damage can
repair spontaneously without intervention. However, if there
is extensive bone damage due to pathologic and traumatic
injuries, there will be a need for reconstructive surgery
and bone transplantation. In this regard, autologous tissue
transplantation would be the best and safest strategy for
bonerepair.Autologousbonegraftistakenfromthepatient’s
own iliac crest, ribs, or calvarium. Unfortunately, access to
autologous bone graft is limited. Furthermore, obtaining an
autograft is associated with morbidity, pain, and infection at
the donor site. Because of such disadvantages other alterna-
tives are needed [2, 3]. Allogenic bone tissue implantation
may be chosen to repair large bone defects, but this bone
substitute also exhibits several drawbacks, which include the
possibility of disease transmission, graft rejection, problems
with graft integration and viability at the recipient site [4].
Emergence of modern bone engineering strategies based
on osteogenic cells, osteoinductive stimulator, and osteo-
conductive scaﬀolds are recognized as potential ways to
create biologic tissue substitutes for regenerating large bone
defects [5]. The choice of cell sources that can eﬃciently
diﬀerentiate into bone tissue is the ﬁrst, important step
during bone engineering. Several cell types can potentially
be used as cellular components in bone engineering. These
include osteoblast, embryonic, and adult stem cells. Among
these candidates, mesenchymal stem cells (MSCs) as adult
stem cells possess some characteristics that make them more
appropriate for use in promoting bone regeneration.
Historically, the deﬁnitive presence of MSCs was discov-
eredabout40yearsagobyFriedensteinetal.inbonemarrow
tissue. They described these cells as mononuclear nonphago-
cytic cells with ﬁbroblast-like phenotype and colongenic po-
tential capable of adhering to the culture surface in a mon-
olayer culture [6]. Later, it has been shown that MSC-like
population were present in a wide range of adult tissues,
including trabecular bone [7], synovium [8], adipose tissue
[9],skeletalmuscle[10],periosteum[11],dermis[12],blood
[13, 14], deciduous teeth [15], amniotic ﬂuid [16], and
umbilical cord blood [17]. Currently, good manufacturing2 Stem Cells International
practice (GMP) has been developed to produce the cells for
use in clinic [18].
It should be mentioned that stem cells are deﬁned by two
key characteristics: the ability of multilineage diﬀerentiation
and the capacity of self-renewal [19]. Of these MSCs possess
multilineage diﬀerentiation potential but have a limited
proliferation capacity since they enter senescence after a
few population doubling in culture [20, 21]. Therefore they
cannot be considered true stem cells. For this reason, in
related literatures the cells have been referred to as by
diﬀerent terminology as colony-forming unit ﬁbroblasts
(CFU-Fs), mesenchymal stromal cells (MSCs), marrow
stromal cells (MSCs), marrow progenitor cells (MPCs), and
marrow stromal ﬁbroblasts (MSFs) [22–28]. Nowadays, the
term mesenchymal stem cells is the dominant term most
frequently used by investigators. Here, the speciﬁc charac-
teristics that make MSCs promising cells for use in bone
regeneration strategies will be discussed.
2. MSCs EscapeEthicalConcerns
Among candidate cells for bone regeneration, embryonic
stem cells (ESCs) possess ethical issues limiting their appli-
cation in bone regeneration. ESCs are derived from the
blastocyst inner cell mass and can be directed toward diﬀer-
entiationintovaryingcelllineages,includingosteoblasticcell
lineages under suitable culture conditions [29–32]. To date,
multiple studies have been conducted on ESCs osteogenic
diﬀerentiation in vitro and their application in bone tissue
engineering with varying scaﬀolds. For example, it has
been shown that culturing ESCs on poly-lactide-co-glycolic
(PLGA) or nanoﬁbers made from PLLA (poly (l-lactic acid))
is associated with high expressions of osteogenic markers,
including alkaline phosphatase and osteocalcin [33, 34].
Despite increasing interest in the application of ESCs in
bone engineering technology, research is highly limited due
t op o l i t i c a li s s u e sa sw e l la se t h i c a lc o n c e r n sa s s o c i a t e d
with these cells. The primary concern is the source from
which these cells are derived. The use of excess embryos
produced in IVF to create ESCs is not acceptable according
to religious and ethical points of view. Additionally, some
reports have indicated that transplantation of ESCs has led
to teratoma formation in the animal model [35, 36]. For
these reasons postnatal adult stem cells, including MSCs that
could be derived from a patient’s own tissues and do not
possess ethical limitations, are considered more appropriate
for clinical use.
3. MSCs AreResidents of Multiple Tissues
MSCs have been reported to constitute about 0.01%–0.001%
of the marrow mononuclear population [37]. These cells can
be isolated from marrow aspirates of the superior iliac crest,
femur, and tibia. For this purpose, marrow cells are usually
enrichedformononuclearcellswithFicollorPercolandthen
plated on culture plastic vessels in order to prepare adherent
cell populations [38]. It has recently been demonstrated
that late plastic adherent MSCs possess higher osteogenic
potential [39]. Alternatively, MSCs can be obtained by the
preparation of a population positive for STRO-1 or CD105.
It has been reported that a population negative for CD45
or Gly-A are from MSCs [40]. By now, many researchers
have studied optimized culture and diﬀerentiation of MSCs
in vitro and their application in regenerating bone defects
in animal models and humans [41–44]. Since collection
of bone marrow is invasive and expansion and osteogenic
diﬀerentiation of marrow-derived MSC seem to be reduced
with advancing age, investigators have attempted to ﬁnd
other tissue sources for MSCs [45]. According to research,
multiple tissues have been found to contain MSC-like
population;ofthese,adiposetissueaswellasbirth-associated
tissues, including umbilical cord and dental pulp, has gained
considerable attention.
The presence of cells with multipotent diﬀerentiation
capacity in adipose tissue is promising due to the ease of
accessibility of adipose tissue and its abundance in the body.
Adipose tissue can be an appropriate substitute for marrow
in regenerative medicine and tissue engineering [46, 47].
Adipose-derived stromal cells (ADSCs) can be derived from
adipose collected by liposuction and lipectomy [48]. ADSCs
a r ea b l et om a i n t a i np r o l i f e r a t i o np o t e n t i a la sw e l la sd i ﬀer-
entiation capacity even in older people. The diﬀerentiation
potentialofADSCsislargelydependentontheconcentration
of ascorbic acid and dexamethasone in culture medium
[49, 50]. By now, many studies conducted on animal models
have conﬁrmed the regenerative potential of ADSCs in bone
defects. The ﬁrst report regarding repair and production of
bone tissue in vivo belongs to Lee et al. who transplanted
ADSCs loaded onto PLGA [51]. Later, Hicok et al. have
noted the production of osteoid matrix when a combination
of ADSCs, hydroxyapatite (HA) and tricalcium phosphate
(TCP), were transplanted in nude mice [52]. In 2004, these
cells were used for the repair of human calvarial defects [53].
To date the eﬀect of various biomaterials, including HA,
human cancellous bone fragments, deproteinized bovine
bone granules, and titanium, has been investigated in terms
of ADSC attachment, proliferation, and diﬀerentiation [54,
55].
The umbilical cord from a newborn baby contains two
arteries and a vein covered with mucus connective tissue rich
in hyaluronic acid, referred to as Wharton’s jelly. According
to studies, MSC-like cells can be derived from various
components of this cord [56]. For example, blood from
an umbilical cord is a rich source for pluripotent cells
which are also referred to as umbilical-cord-blood-derived
MSCs (UCB-MSCs). These cells are quite similar to marrow-
derived MSCs and have osteogenic potential in an optimized
culture [57–59]. Many investigations have thus far been
conducted on bone engineering by using these cells and
various scaﬀolds [60, 61].
Severalstemcelltypesindentaltissuehavebeenreported
including dental pulp stem cells (DPSCs), stem cells from
human exfoliated deciduous teeth (SHED), stem cells of
the apical papilla (SCAP), periodontal ligament stem cells
(PDLSCs), and dental follicle progenitor cells (DFPCs)
[15, 62]. Since DPSCs can be easily isolated by enzymatic
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regarding bone engineering with these cells and appropriate
3D scaﬀolds, including HA/TCP and polylactic-co-glycolic
acid (PLGA) [63, 64].
4. MSCs CanEfﬁciently Differentiatealong
anOsteogenic Lineage
MSCs osteogenic property was the ﬁrst reported diﬀerentia-
tion capacity when they were discovered. Indeed, even prior
to deﬁnitive isolation of MSCs from bone marrow, some
transplantation experiments clearly showed the osteogenic
capacity of marrow tissue. Friedenstein et al. were the ﬁrst
to isolate and describe the cellular equivalent of osteogenic
features of marrow tissue [65].
Osteogenic diﬀerentiation is a highly programmed pro-
cess that consists of many stages including proliferation, dif-
ferentiation, matrix deposition, mineralization, and matrix
maturation. The general protocol for in vitro bone diﬀer-
entiation of MSCs involves incubation of cell monolayer in
a culture medium containing dexamethasone, beta glycerol
p h o s p h a t e ,a n da s c o r b i ca c i df o rap e r i o do ft w ot ot h r e e
weeks [66]. Dexamethasone is a synthetic glucocorticoid
that stimulates MSC proliferation and is essential for their
osteogenic diﬀerentiation [67, 68]. Although the mechanism
of dexamethasone’s eﬀect is not well known, it has been
speculated that this reagent exerts its eﬀects through upreg-
ulation of the beta catenin-like molecule TAZ, which results
in up-regulation of Runx2-related transcription factor and
osteogenic diﬀerentiation [69]. The optimal concentration
of this reagent for MSC bone diﬀerentiation is about 10nM,
which corresponds with its physiologic concentrations [70].
Organic phosphate released after enzymatic hydrolysis of
beta glycerol phosphate plays an important role in matrix
mineralization. This free phosphate is usually applied in 5–
10mM concentrations for MSC bone diﬀerentiation [71].
Ascorbic acid is a cofactor in the hydroxylation of prolins
and lysine moiety of collagen molecules and is the abundant
protein in ECM. This reagent is used in 50–500μMc o n c e n -
trations [72]. In addition to these osteogenic supplements,
there are other osteogenic factors including (1,25-D3) 1,25-
dihydroxyvitamin and BMPs (BMP2) [73].
MSC in vitro bone diﬀerentiation results from the acti-
vation of some well-known molecular signaling pathways.
Each osteogenic reagent activates a molecular pathway that
leads to a diﬀerentiated phenotype. Although the osteogenic
eﬀects of a number of these reagents have long been known,
speciﬁcpathwaysbywhichtheeﬀectsaremediatedremainto
be clariﬁed. The activation of wingless-type MMTV integra-
tion site family of the protein (Wnt) signaling pathway [74],
mitogen-activated protein kinase (MAPK)signaling pathway
[75], TGF beta and BMP signaling pathways [76], and RHO-
GTPase signaling pathway [77] has been established in MSC
bone diﬀerentiation.
Activation of signaling pathways by osteogenic supple-
ments eventually leads to activation of osteoblast-speciﬁc
signalproteins andspeciﬁcosteoblastic transcription factors.
Cbfa1 (core binding factor alpha 1) also called as Runx2
(runt-related gene 2) is one of the most studied transcription
factors expressed in MSCs upon their commitment toward
osteogenicdiﬀerentiation[78,79].Runx2,asamasterswitch,
adheres to osteoblast-speciﬁc cis-acting element (OSE2) in
thegenepromoterregionstimulatingtheexpressionofbone-
speciﬁc genes such as coll I, osteocalcin, osteopontin, and
alkaline phosphatase [80]. Osterix is another transcription
factor involved in MSC bone diﬀerentiation, which has been
clearly shown in murine MSCs where they were retrovirally
transduced with the osterix gene [81]. Addition of dexam-
ethasone to the culture of murine calvarial osteoblasts has
been reported to induce expression of osterix as well as
Runx2 genes [82].
OptimalconditionsforMSCinvitrobonediﬀerentiation
are well been established. For example, the addition of
rhBMP-2 to osteogenic medium can facilitate proliferation
and osteogenic diﬀerentiation of BMSCs both in vitro and in
vivo. The use of alpha MEM versus DMEM and application
of low-passaged versus high-passaged cells can end with
higher expression of osteogenic genes and more culture
mineralization [83–85]. Studies on scaﬀold designing and
the eﬀect of biomaterial on bone repair have indicated that
calciumphosphate-basedscaﬀolds,including hydroxyapatite
(HA) and tricalcium phosphate (TCP), are more appropriate
for bone engineering due to their osteoconductive properties
[86].Applyingﬂuidshearstress(FSS)ontheMSCosteogenic
culture increases the expression of bone-speciﬁc genes and
deposition of mineralized matrix. FSS mediates its eﬀects
through regulation of mechanosensitive signaling molecules,
including ion channel and integrins, which are able to
convert mechanical into chemical signals [87, 88].
5. Nonimmunogenic Properties of MSCs
MSCs possess immunologically speciﬁc characteristics;
therefore they would be general donors for therapeutic
applications. Immunologic phenotypes of MSCs are MHC
I+, MHC II−,C D4 0 −, CD80−, and CD 86− [89]. Graft
rejection by the immune system occurs when T cells are
fully activated. T cells require two signals to become fully
activated. The ﬁrst signal is provided through the T-cell
receptor which interacts with peptide-MHC molecule 1
on the membrane of antigen-presenting cells (APC). A
second signal, the costimulatory signal, is provided by
the interaction between co-stimulatory molecules, including
CD80andCD86thatareexpressedonthemembraneofAPC
and the T cell [90]. MSCs do not trigger T-cell activation
owing to the absence of CD80 and CD86 in their membrane
[91]. The immunosuppressive nature of MSCs has been
shown in skin allografts of baboon models.
According to research, MSCs secrete soluble factors that
inhibit CD4+ and CD8+ T-cell activation as well as prolifer-
ation. Among these factors are indoleamine 2,3-dioxygenase
(IDO), nitric oxide, TGF-beta, and prostaglandin E 2 [92–
95]. It has been demonstrated that MSCs stop the B-cell
cycle at the G0/G1 stage and inhibit their diﬀerentiation into
plasma cells [96, 97]. Ramasamy et al. have indicated that
BMSCs are able to inhibit dendritic cell (DC) diﬀerentiation
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DCs are able to eﬃciently present antigens to lymphocytes.
According to research, monocytes diﬀerentiate into DCs in
the presence of MSCs [99].
Immunomodulatory features of MSCs make them an
important cellular candidate for cell-based treatment of
tissue defects in an allogenic setting. For this reason, there is
hopethatMSCscouldreplaceautologousandallogenicbone
grafts which have known exhibited limitations in terms of
availability and risk of pathogen transmission, respectively.
At the allogenic approach, it will be possible to develop a
cell bank to maintain MSCs from every donor for use in
cell therapy. Prior to routine application of the cells in the
clinic, an exact understanding of the immunologic features
of MSCs and the underlying mechanism of action is needed
[100, 101].
6. Injury-SeekingCapabilityof MSCs
One of the most important capabilities of MSCs is their
migration capacity in response to signals produced by an
injured bone [102, 103]. At the injury site, MSCs could
possibly help with repair in two ways: (1) they diﬀerentiate
t ot i s s u ec e l l si no r d e rt or e s t o r el o s tm o r p h o l o g ya sw e l la s
function, and (2) MSCs secrete a wide spectrum of bioactive
factors that help to create a repair environment by possessing
antiapoptotic eﬀects, immunoregulatory function, and the
stimulationofendothelialprogenitorcellproliferation[103].
The precise mechanisms of cell traﬃcking in blood,
transmigration through endothelial cell, and homing to the
injured site are not thoroughly understood, but it has been
speculated that chemokines and their receptors regulate this
process [89]. Chemokines (chemotactic cytokines) are small
proteins (8–10 KDs) with a capacity for creating a chemical
environment appropriate for the migration of lymphocytes,
neutrophils, and other immune cells towards inﬂammation,
angiogenesis, and the organogenesis site. On the other hand,
MSCs express a series of chemokine receptors that play a
role in their migration in response to a chemokine gradient
produced at the damaged site. These chemokine receptors
include CCR1, CCR7, CCR9, CCR3, CCR4, CCR5, and
CX3CR1 [104]. CXCR4 receptor and its speciﬁc chemokine
(stromal cell-derived factor1 (SDF1)) play an important role
in stem cell traﬃcking, particularly HSCs [105]. It has been
proposed that SDF1/CXCR4 could be a homing signal for
MSCs in bone repair.
Kitaori et al. have reported that SDF1 expressed by
periosteum mediates bone repair in the murine femoral
model by recruiting MSCs to the fracture site [106]. The
SDF1 gradient causes both host as well as infused MSCs
to migrate towards the injured area. MSC migration has
been proven in clinical trials performed by Horwitz et
al. in which MSCs were injected to regenerate bone in
six patients who suﬀered from osteogenesis imperfecta,
where osteoblasts secrete defective collagen I resulting in
osteopenia.Observationsindicatedthatin5outof6children
who received allogenic MSCs, cell migration to various
tissues that included bone, skin, and marrow stroma was
observed [107]. Transplantation of MSCs was followed by
increased formation of compact bone and reduction in
fracture frequency.
Considering the relationships of cell migration with the
chemokine concentration gradient, it can be concluded that
theapplicationofMSCsmustbeperformedatthetimewhen
the chemokine concentration gradient is established at an
adjacent area to the injured site.
7. MSCs as Vehicles for Bone Gene Therapy
MSCs could be ideal carriers for therapeutic genes at a
cell-mediated gene delivery strategy owing to their unique
characteristics that include ease of isolation, culture, and
expansion as well as their immunomodulatory property
[108].
In the normal process of bone development and repair,
cytokinesandosteoinductivegrowthfactorsplayamajorrole
by recruiting osteogenic progenitors at the bone formation
site and promoting their diﬀerentiation into bone cell
lineages [109]. Therefore, the application of such factors
which include related recombinant growth factors in large
areas of bone damage would enhance new bone formation.
However the problem is that recombinant growth factors
have a limited half-life that limits their sustained supply into
damaged tissue. To overcome this limitation, gene transfer
strategies using cellular carriers have been proposed. This
strategy oﬀers the sustained delivery of the osteogenic factor
to the damaged area [110]. Genetic manipulation of MSCs
can be achieved by transduction using viral vectors such as
theadenovirus(Ad)[111]ortransfectionbynonviralvectors
such as liposomes [112]. Viral vectors have the advantage of
high eﬃciency but trigger the immune system. In addition,
they possess varying capacity to transfer genes into dividing
and nondividing cells [113]. Non-viral vectors possess the
advantage of not being toxic [114].
Many investigators have tried to regenerate bone by
transfecting MSCs with the BMP gene. For example,
Lieberman et al. have indicated that autologous BMSCs
expressing Ad-BMP2 can considerably promote segmental
femoral defects in rat models when compared with BMSCs
expressing Ad-LacZ [115]. Transplantation of Ad-BMP2-
MSCs in rabbits has been reported to be associated with
new bone formation [116]. In spite of the multiple studies
that have focused on temporary expression of factors using
the adenovirus vector, Gysin et al. have observed permanent
expression of BMP4 using retrovirus in BMSCs which lead
to repair of critical sized calvarial defects in rats [117]. In
o n es t u d y ,L i ne ta l .h a v ec o m p a r e dB M P 4 - t r a n s f e c t e dM S C s
from marrow and adipose tissue in bone repair of a rabbit
model and found no signiﬁcant diﬀerence [118].
It has been shown that Ad-Runx2-MSCs transplanted in
murine calvarial defects produce more bone tissue compared
to MSCs [119]. Recent studies have focused on simultaneous
application of BMPs and RUNX2. When these two factors
were entered into an immortal MSCs line and injected into
mice, considerable bony ossicle with marrow cavity was
observed (compared to the application of cells that expressed
Ad-BMP2) [120]. Although no clinical trial to date has been
conducted using genetically modiﬁed MSCs, studies haveStem Cells International 5
indicated that such a strategy would be more eﬀective in
enhancing bone repair.
8. Conclusion
MSCs as adult stem cells are free from ethical concerns,
residents of multiple tissues, able to eﬃciently diﬀerentiate
along an osteogenic lineage, possess non-immunogenic
properties, have injury-seeking capabilities, and can be used
as vehicles for bone gene therapy. These characteristics
make MSCs safe and promising candidates for use in bone
engineering and regeneration. Currently, several clinical
trials are being performed on problematic human bone
lesions, including nonunion fractures, delayed union, bone
cysts, and bone neoplasms, among others. These ongoing
registered trials are available at the following clinical trial
website: http://clinicaltrials.gov/.
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